Pfizer Inc. (PFE)

NYSE: PFE · Real-Time Price · USD
25.61
-0.28 (-1.08%)
Dec 19, 2024, 12:57 PM EST - Market open
-1.08%
Market Cap 145.13B
Revenue (ttm) 59.38B
Net Income (ttm) 4.25B
Shares Out 5.67B
EPS (ttm) 0.74
PE Ratio 34.40
Forward PE 9.82
Dividend $1.72 (6.72%)
Ex-Dividend Date Jan 24, 2025
Volume 21,407,742
Open 25.70
Previous Close 25.89
Day's Range 25.58 - 26.09
52-Week Range 24.48 - 31.54
Beta 0.59
Analysts Buy
Price Target 32.31 (+26.16%)
Earnings Date Jan 28, 2025

About PFE

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women’s health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and po... [Read more]

Sector Healthcare
Founded 1849
Employees 88,000
Stock Exchange NYSE
Ticker Symbol PFE
Full Company Profile

Financial Performance

In 2023, Pfizer's revenue was $58.50 billion, a decrease of -41.70% compared to the previous year's $100.33 billion. Earnings were $2.12 billion, a decrease of -93.25%.

Financial Statements

Analyst Forecast

According to 14 analysts, the average rating for PFE stock is "Buy." The 12-month stock price forecast is $32.31, which is an increase of 26.16% from the latest price.

Price Target
$32.31
(26.16% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Pfizer Invites Public to View and Listen to Webcast of February 4 Conference Call with Analysts

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:30 a.m. EST on Tuesday, ...

2 hours ago - Business Wire

Roam For the Holidays: Grindr Offers Free Access to Their Popular Travel Feature

WEST HOLLYWOOD, Calif.--(BUSINESS WIRE)--From December 22 to January 2, people on Grindr across the globe can experience Roam, a popular new feature, free of charge.

Other symbols: GRND
6 hours ago - Business Wire

Pfizer Momentum Shift Makes Me Less Bullish (Technical Analysis)

Pfizer Inc.'s technical indicators have shifted from bullish to bearish, with the stock now trading below its 30-week EMA and showing bearish momentum. Volume analysis indicates recent institutional s...

1 day ago - Seeking Alpha

Is Pfizer Stock Undervalued?

Pfizer stock (NYSE: PFE) was up 5% on Tuesday, December 17, after the company announced an optimistic outlook for 2025. The company expects its revenue to be in the range of $61 billion to $64 billion...

1 day ago - Forbes

Final Trade: GOOG, SAIA, X, PFE

The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.

Other symbols: SAIAGOOGGOOGLX
1 day ago - CNBC Television

Pfizer climbs 4% on 2025 outlook

Evan David Seigerman, BMO analyst, joins 'Closing Bell Overtime' to talk Pfizer's 2025 outlook.

1 day ago - CNBC Television

Stock Of The Day: Is Pfizer About To Break Out? Expect A New Uptrend If Resistance Breaks

Shares of Pfizer Inc.  PFE are making a large move higher Tuesday. But the stock has run into resistance.

2 days ago - Benzinga

Pfizer Inc. (PFE) Full-Year 2025 Financial Guidance Conference Call (Transcript)

Pfizer Inc. (NYSE:PFE) Full-Year 2025 Financial Guidance Conference Call December 17, 2024 8:30 AM ET Company Participants Francesca DeMartino - Chief IRO and SVP Albert Bourla - Chairman and CEO Dav...

2 days ago - Seeking Alpha

Pfizer Stock Rises as 2025 Outlook in Line With Expectations

Pfizer (PFE) shares rose Tuesday morning after the pharmaceutical company affirmed its full-year 2024 projections and issued 2025 revenue and adjusted profit guidance in line with analysts' estimates.

2 days ago - Investopedia

Guggenheim: Can see Pfizer reaching $10 billion in sales by 2030

Vamil Divan, Guggenheim Securities analyst, joins 'Squawk on the Street' to discuss Pfizer's guidance, how optimistic Divan is on Pfizer's product pipeline, and some of the complaints Pfizer has heard...

2 days ago - CNBC Television

Pfizer Does Not Anticipate Material Changes To US Vaccine Policy From The Incoming Administration In 2025

On Tuesday, Pfizer Inc. PFE released its full-year 2025 financial guidance, projecting revenues between $61.0 billion and $64.0 billion compared to a consensus of $63.28 billion.

2 days ago - Benzinga

Pfizer Sees 2025 Revenue in Line With Wall Street Views

Pfizer forecast 2025 revenue and earnings in line with market expectations, despite a $1 billion hit from the redesign of federal drug benefits.

2 days ago - WSJ

Pfizer Stock Rises as Drug Giant Sees 2025 Revenue of $61 Billion to $64 Billion

The company anticipates adjusted earnings of between $2.80 and $3 a share in 2025. Analysts had been expecting adjusted earnings of $2.86.

2 days ago - Barrons

Pfizer forecasts 2025 profit in line with expectations

Drugmaker Pfizer on Tuesday said it was expecting its 2025 profits to be nearly in line with Wall Street expectations as it seeks to fend off criticism over its turnaround strategy from activist hedge...

2 days ago - Reuters

Pfizer Provides Full-Year 2025 Guidance and Reaffirms Full-Year 2024 Guidance

NEW YORK--(BUSINESS WIRE)--Pfizer 2025 Financial Guidance press release.

2 days ago - Business Wire

Insurer stocks fall after Trump says 'we're going to knock out the middleman'

Shares of health insurers operating pharmacy benefit managers fell on Monday after U.S. President-elect Donald Trump called them middlemen who drive up costs and said he plans to eliminate their role.

Other symbols: CICVSLLYUNH
2 days ago - Reuters

What To Expect When Pfizer Outlines Its 2025 Financial Outlook On Tuesday?

Pfizer Inc. PFE will conduct an investor call on Tuesday to provide full-year 2025 financial guidance.

2 days ago - Benzinga

Pfizer: Lowest Levels In A Decade Is An Opportunity With A Dividend Yield Exceeding 6.5%

Pfizer's shares have significantly underperformed, but the current valuation and high dividend yield present a compelling value play. Despite revenue declines and potential regulatory risks, Pfizer re...

3 days ago - Seeking Alpha

Pfizer: Irrational Anti-Vaccine Fear

Pfizer's stock has become appealing due to irrational vaccine fears. Market fears about RFK Jr.'s potential anti-vaccine stance are likely overblown, as neither he nor Trump have indicated plans to bl...

4 days ago - Seeking Alpha

Reader Mailbag: Is Pfizer (PFE) a Good Deal Right Now?

November was an interesting month for pharmaceutical companies in general. President-elect Trump officially announced that Robert F.

5 days ago - ETF Trends

Pfizer Declares First-Quarter 2025 Dividend

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared an increase in the quarterly cash dividend on the company's common stock to $0.43 for the first-...

6 days ago - Business Wire

Pfizer's IBRANCE® in Combination with Standard-of-Care Therapies Extends Median Progression-Free Survival by Over 15 Months in Phase 3 PATINA Study in Patients with HR+, HER2+ Metastatic Breast Cancer

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) and Alliance Foundation Trials, LLC (AFT) today announced results from the Phase 3 PATINA trial demonstrating that the addition of IBRANCE® (palbocicl...

7 days ago - Business Wire

Pfizer: Peer-Leading Dividend And Potential Substantial Shareholder Returns

Pfizer's share price struggles despite a strong asset portfolio and $10 billion annual R&D investment, with significant Seagen acquisition integration ongoing. Q3 2024 results show 32% YoY revenue inc...

7 days ago - Seeking Alpha

Pfizer Stock: A Golden Buying Opportunity (Rating Upgrade)

I upgrade Pfizer to "Strong Buy" due to its undervaluation, strong pipeline, and operational growth despite recent stock price declines. Pfizer's Q3 FY2024 earnings showed significant revenue and EPS ...

8 days ago - Seeking Alpha

Pfizer Invites Public to View and Listen to Webcast of December 17 Conference Call with Analysts to Provide Full-Year 2025 Financial Guidance

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 8:30 a.m. EST on Tuesday, D...

9 days ago - Business Wire